ID   SKNO-1
AC   CVCL_2196
SY   Skno-1; SKNO1
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473440
DR   BioSample; SAMN10989585
DR   cancercelllines; CVCL_2196
DR   Cell_Model_Passport; SIDM01864
DR   Cosmic; 787478
DR   Cosmic; 975301
DR   Cosmic; 1149337
DR   Cosmic; 1281353
DR   Cosmic; 1524841
DR   Cosmic; 2306239
DR   Cosmic; 2690678
DR   DepMap; ACH-001656
DR   DSMZ; ACC-690
DR   DSMZCellDive; ACC-690
DR   GEO; GSM236805
DR   GEO; GSM236841
DR   IARC_TP53; 16154
DR   JCRB; JCRB1170
DR   Wikidata; Q54954758
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7772516;
RX   PubMed=9738977;
RX   PubMed=10637496;
RX   PubMed=11753612;
RX   PubMed=15843827;
RX   PubMed=18385756;
RX   PubMed=25984343;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Characteristics: CSF2 dependent.
CC   Doubling time: 48-72 hours (PubMed=7772516); 24 hours (PubMed=25984343); ~35-50 hours (DSMZ=ACC-690); ~38 hours (Note=Lot 06112012), 52-57 hours (Note=Lot 02032016) (JCRB=JCRB1170).
CC   HLA typing: A*02:06:01,31:01:02; B*40:02:01,46:01:01; C*01:02:01,03:04:01; DRA*01:01:01,01:02:02; DRB1*14:02:01,14:02:01 (DSMZCellDive=ACC-690).
CC   Sequence variation: Gene fusion; HGNC; 10471; RUNX1 + HGNC; 1535; RUNX1T1; Name(s)=RUNX1-RUNX1T1, AML1-ETO (PubMed=11753612; PubMed=15843827).
CC   Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asn822Lys (c.2466T>A) (N818K); ClinVar=VCV000375931; Zygosity=Homozygous (PubMed=18385756; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=7772516; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His368Arg (c.1103G>A); Zygosity=Homozygous (PubMed=7772516; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: shRNA library screening.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.83%; Native American=0%; East Asian, North=90.65%; East Asian, South=3.5%; South Asian=1.23%; European, North=0.2%; European, South=2.59% (PubMed=30894373).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DSMZ; JCRB
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8,11
ST   D16S539: 10,11
ST   D18S51: 13,14
ST   D19S433: 13,15
ST   D21S11: 29,30
ST   D2S1338: 19
ST   D3S1358: 16
ST   D5S818: 10,13
ST   D7S820: 10,12
ST   D8S1179: 14,15
ST   FGA: 23
ST   Penta D: 9
ST   Penta E: 11,12
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 14,17
DI   NCIt; C7961; Adult acute myeloid leukemia with maturation
DI   ORDO; Orphanet_98834; Acute myeloblastic leukemia with maturation
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 29
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=7772516; DOI=10.1111/j.1365-2141.1995.tb08418.x;
RA   Matozaki S., Nakagawa T., Kawaguchi R., Aozaki R., Tsutsumi M.,
RA   Murayama T., Koizumi T., Nishimura R., Isobe T., Chihara K.;
RT   "Establishment of a myeloid leukaemic cell line (SKNO-1) from a
RT   patient with t(8;21) who acquired monosomy 17 during disease
RT   progression.";
RL   Br. J. Haematol. 89:805-811(1995).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=10637496; DOI=10.1038/sj.leu.2401604;
RA   Drexler H.G., Fombonne S., Matsuo Y., Hu Z.-B., Hamaguchi H.,
RA   Uphoff C.C.;
RT   "p53 alterations in human leukemia-lymphoma cell lines: in
RT   vitro artifact or prerequisite for cell immortalization?";
RL   Leukemia 14:198-206(2000).
//
RX   PubMed=11753612; DOI=10.1038/sj.leu.2402318;
RA   Xiao Z., Greaves M.F., Buffler P., Smith M.T., Segal M.R., Dicks B.M.,
RA   Wiencke J.K., Wiemels J.L.;
RT   "Molecular characterization of genomic AML1-ETO fusions in childhood
RT   leukemia.";
RL   Leukemia 15:1906-1913(2001).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=18385756; DOI=10.1038/leu.2008.61;
RA   Becker H., Pfeifer D., Afonso J.D., Nimer S.D., Veelken H.,
RA   Schwabe M., Lubbert M.;
RT   "Two cell lines of t(8;21) acute myeloid leukemia with activating KIT
RT   exon 17 mutation: models for the 'second hit' hypothesis.";
RL   Leukemia 22:1792-1794(2008).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//